Swapping PEG for heparosan on mRNA nanoparticles boosted immune response to COVID spike protein in mice
RNA medicine had a big week in the lab — new coatings, smarter targeting, and one uncomfortable reminder that generating T cells doesn't always translate to saving lives.
Here's what moved the field.
A PEG-free nanoparticle coating just made mRNA vaccines work harder 🧫
- Most mRNA nanoparticles are wrapped in polyethylene glycol (PEG) to stay stable in the body — but PEG can blunt immune responses and trigger anti-PEG antibodies over time. Researchers swapped it for heparosan, a natural sugar polymer, and the results were striking.
- In immune cells, heparosan-coated particles drove up to ~10-fold more mRNA expression than PEG-coated versions. Live-cell imaging showed why: the heparosan particles spent significantly less time trapped in late endosomes and lysosomes — the cellular garbage disposal — meaning more mRNA escaped into the cytosol where it could actually do something.
- In mice given a COVID spike protein mRNA, heparosan-coated particles produced stronger antibody responses after repeated subcutaneous doses, with no signs of toxicity or immune cell disruption in the spleen.
Why it matters: PEG is in every FDA-approved RNA nanoparticle right now. A viable alternative that improves both escape efficiency and immune response — without apparent safety trade-offs — is exactly the kind of upstream fix the field has been hunting for.
Key Findings
A robot can now design better mRNA nanoparticles faster than a lab team ⚙️
- Researchers built a fully autonomous, pilot-scale platform that uses real-time light-scattering feedback, Bayesian optimization, and automated experiment design to tune nanoparticle size without human intervention.
- The system rapidly mapped complex relationships between manufacturing conditions and particle quality, then built a predictive model linking process inputs to physical outputs — compressing what normally takes weeks of empirical trial-and-error.
Researchers tracked mRNA distribution in rodents
- A rodent study compared where an experimental treatment accumulated. The researchers detected differences between organs.
- Gastric delivery achieved an order of magnitude greater pancreas accumulation than intravenous injection. Buccal (cheek) delivery targeted local lymphatic tissue, and ovalbumin mRNA given that way produced antibody levels equivalent to intramuscular injection.
New lipids designed for circular RNA outperformed Moderna's benchmark by 28-fold in muscle cells
- Circular RNA is more stable than linear mRNA but harder to deliver — its closed-loop shape changes how it interacts with lipid nanoparticles. A new class of ionizable lipids with aminoethoxy head units and branched biodegradable tails was purpose-built for the job.
- One candidate produced a stronger response in the animal study. Its safety and performance in humans remain unknown.
BioNTech's shared-antigen cancer vaccine failed its phase II/III trial — and the field is still arguing about why
- BNT113, an mRNA vaccine targeting HPV16 proteins found in head and neck cancer, did not significantly delay tumor progression in a late-stage trial — the latest in a pattern of shared-antigen cancer vaccines that generate measurable T-cell responses but fail to improve outcomes.
- Researchers argue the vaccines are immunologically functional, and that the real problem is patient selection and endpoint choice: trials measuring tumor progression may be the wrong yardstick when overall survival is what counts.
Lung-targeting mRNA nanoparticles used immune cells as a delivery shuttle — and shrank tumors
- Researchers found that an experimental treatment reached lung tissue in mice.
- When loaded with p53 mRNA — a tumor-suppressor gene commonly lost in cancer — and combined with checkpoint immunotherapy, these particles suppressed lung metastasis from triple-negative breast cancer in mice. A prodrug variant co-delivered a second anticancer agent in the same particle.
Lipoproteins in blood don't just coat nanoparticles — they restructure them from the inside
- When lipid nanoparticles enter the bloodstream, plasma proteins adsorb onto their surface — a well-known phenomenon called the protein corona. New evidence suggests the story is more disruptive: lipoproteins actually exchange lipid molecules with the nanoparticle membrane, physically reorganizing its internal structure.
- Cubic-phase particles underwent pronounced remodeling — changing size and internal lattice order — while hexagonal-phase particles stayed structurally stable despite similar lipid exchange. The two particle types also showed distinct cellular uptake profiles as a result.
Implications
The throughline this week: getting mRNA into the right cell at the right time is still the hard part. New coatings, autonomous manufacturing, and organ-specific routes are chipping away at the problem — but the gap between a strong immune readout in mice and a survival benefit in humans remains stubbornly unresolved.
Studies in this issue
Primary sources used for this newsletter.
- Improving mRNA delivery by coating lipid nanoparticles with heparosan sugars to reduce cell compartment trappingmain storyACS nano2026-10-23PMID 42915664
- Using mRNA Nanoparticles Delivered to the Gut for Whole-Body Vaccines and Metabolic Treatmentkey findingACS nano2026-10-23PMID 42917207
- Self-Directed Design of Lipid Nanoparticleskey findingACS nano2026-10-23PMID 42917196
- How Protein Coating Changes the Inside Structure of Fat-Based Nanoparticleskey findingACS nano2026-10-23PMID 42915048
- Cancer Vaccines Targeting Common Tumor Markers Often Fail to Workkey findingCancer discovery2026-10-20PMID 42899601
- Delivering Circular RNA Inside and Outside Cells Using Special Branched Lipid Nanoparticleskey findingJournal of the American Chemical Society2026-10-23PMID 42912353
- Special Ionizable Lipids That Deliver mRNA Efficiently to the Lungs Through Cell-to-Cell Transportkey findingNano letters2026-10-23PMID 42917407
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.